Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Soluble biomarker signature to predict outcome of patients with non-small-cell lung cancer (NSCLC) treated with anti-PD1/PDL1 monoclonal antibodies.

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e20685

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e20685)

Author(s): Javier Garde-Noguera, Eloisa Jantus-Lewintre, Sandra Gallach, Jose Vidal-Martinez, Ana Blasco, Jose Garcia Sanchez, Feiyu Zhang, Francisco Aparisi, Beatriz Honrubia Peris, Lauren Condori Farfan, Susana Torres Martinez, Nuria Piera Molons, J. Murado-Pardo, R. Gisbert-Criado, Silvia Calabuig-Fariñas, Carlos Camps; Hospital General Universitario de Valencia, Valencia, Spain; Laboratorio de Oncología Molecular, FIHGUV, CIBERONC, Departamento de Biotecnología, Universitat Politècnica de València, Valencia, Spain; Laboratorio de Oncologia Molecular, Fundación para la Investigación del Hospital General Universitario de Valencia, CIBERONC, Valencia, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Servicio de Oncología Médica, Hospital General Universitario de Valencia (HGUV), Valencia, Spain; Hospital Arnau de Vilanova, Valencia, Spain; Laboratorio de Oncología Molecular, Fundación de Investigación Hospital General Universitario de Valencia, Valencia, Spain; Servicio de Oncología Médica, Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Laboratorio de Oncología Molecular, Fundación para la Investigación, Hospital General Universitario de Valencia-CIBERONC, Valencia, Spain; Serivicio de Analisis Clínicos, Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Servicio de Análisis Clínicos, Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Laboratorio de Oncología Molecular, FIHGUV, CIBERONC, Departament de Patologia, Universitat de València, Valencia, Spain; Servicio de Oncología Médica, Hospital General de Valencia, Valencia, Spain

Abstract Disclosures

Abstract:

Background: Immunotherapy with anti-PD1/PDL1 monoclonal antibodies has become the second line standard treatment for most patients diagnosed of advanced Non-Small-Cell lung cancer (NSCLC). The aim of this study is to assess the utility of circulating biomarkers such as sPDL1, sPDL2, sCD137, sIDO, sTIM3, sCD28, sCD27, sCTLA4, sHVEM, sLAG3, sCD80 and sGITR for predicting efficacy of immunotherapy with anti-PD1/PDL1 therapies. Methods: Blood samples were collected before treatment from 50 NSCLC patients who received anti PD1/PDL1 therapies (second line). Plasma biomarkers´ levels were measured by Multiplex bead-based assays. Continuous variables were categorized using the median as a cut-off. Non parametric test were used for correlations between analytical variables and clinical-pathological parameters and response rate analysis. For survival analysis (progression free survival-PFS and overall survival-OS) Kaplan Meier curves and long-rank test were performed. Results: 50 patients met inclusion criteria. Biomarkers associated with better outcome in terms of Response Rate or PFS were sPDL1, sIDO, sCD137 and sGITR. Median plasma levels of sPDL1, sCD137, sIDO and sGITR were 80.5, 168.7, 64.92s and 114.43 ng/ml respectively. ORR was higher in patients with high levels of CD137 (75 vs 25%, p = 0.28), GITR (83.3 vs 16.7%, p = 0.009) and sPDL1 (66.7 vs 33.3%, p = 0.07). Median PFS was significantly higher for patients with high sPDL1 levels (NR vs 3 months, p = 0.017), and there was a favourable trend for patients with higher serum levels of CD137 (NR vs 5.07, p = 0.11), sIDO (NR vs 5.57 months, p = 0.08); and sGITR (14.33 vs 5.57 months, p = 0.16). Combination of these biomarkers allowed the identification of three groups: group1 (0-1 positive biomarker), group2 (2 positive biomarkers) and group 3 (3 or 4 positive biomarkers), with significant differences in ORR (8.3 vs 25 vs 66.7%, p = 0.01), PFS (median 3.2, 1.1 and NR months, p = 0.01) and OS (median 2.3, 5.0 and NR months, p = 0.02). Conclusions: Circulating immune markers can be reliable detected in plasma of advanced NSCLC patients. In patients treated with anti-PD1 antibodies. sCD137, sIDO, sGITR and sPDL1 seem to be related to the degree of response or PFS. Combination of these biomarkers might be helpful to predict efficacy of immunotherapy treatment.

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...